ÉöÔ࣬Ë׳ơ°Ñü×Ó¡±£¬ÊÇÈËÌåÃÚÄòϵͳÖÐ×îÖ÷ÒªµÄÆ÷¹Ù£¬¶ÔÈËÀ࿵½¡¾ßÓÐÖÁ¹ØÖ÷ÒªµÄ×÷Óá£ËüµÄ»ù±¾¹¦Ð§ÊÇÌìÉúÄòÒº£¬É¨³ýÌåÄÚ´úл·ÏÎÖØÎüÊÕÆÏÌÑÌÇ¡¢°±»ùËá¡¢ÄÆÀë×Ó¡¢Ë®µÈÖÖÖÖÓÐÓÃÎïÖÊ£¬±ðµÄÉö»¹¾ßÓе÷ÀíѪҺµç½âÖʺÍËá¼îƽºâ£¬Éø͸¼¤ËصÈÖ÷Òª¹¦Ð§¡£
ÉöÔàλÓÚ¼¹ÖùÁ½²à£¬×óÓÒ¸÷Ò»£¬ºìºÖÉ«£¬ÐÎËƲ϶¹£¬Íâòƽ»¬£¬Ã¿¸öÉöµÄÖØÁ¿»òÐíÔÚ100¡ª200¿Ë£¬ÊܸÎÔàÓ°Ï죬ÓÒÉöÒ»Ñùƽ³£±È×óÉöÂÔµÍ1-2ÀåÃס£ÉöÔàƤÖʳʺìºÖÉ«£¬·ÖΪÍâÔµºÍÄÚÔµÁ½²¿·Ö£¬ÉöÍâԵΪ͹Ã棬ÄÚԵΪ°¼Ã棬°¼ÃæÖв¿ÎªÉöÃÅ£¬ËùÓÐѪ¹Ü¡¢Éñ¾¼°Áܰ͹ܾùÓɴ˽øÈëÉöÔ࣬ÉöÓÛÔòÓÉ´Ë×ß³öÉöÍâ[1]¡£
ͼ1.ÉöÔàµÄλÖúͽṹ
Éöµ¥Î»ÊÇÉöÔà½á¹¹ºÍ¹¦Ð§µÄ»ù±¾µ¥Î»£¬ÓÉÉöСÌåºÍÉöС¹Ü×é³É£¬ÉöСÌåÓÖÓÉÉöСÇòºÍÉöСÄÒ×é³É¡£Ã¿¸öÉöÔàÔ¼ÓÐÒ»°Ù¶àÍò¸öÉöµ¥Î»£¬Éö²»¿ÉÔÙÉúеÄÉöµ¥Î»¡£Éöµ¥Î»ÊÇÉöÔಿλÎïÖʽ»Á÷ºÍÄÜÁ¿´«ÊäµÄÖ÷Ҫϵͳ£¬°üÀ¨ÉöСÇòÂ˹ýѪҺÐγÉÔÄò£¬ÉöС¹Ü¡¢ÜöÝ͹ÜÖØÎüÊÕÓªÑøÎïÖʺÍëϸѪ¹ÜÎïÖʽ»Á÷Àú³Ì¡£Òò´Ë£¬Éöµ¥Î»ÊÇÉöÔà΢ѻ·ÏµÍ³Ê©Õ¹×÷ÓõĻù±¾µ¥Î»£¬¶ÔÉöÔà¸÷¹¦Ð§µÄµÄÕý³£ÔËתÆðמöÒéÐÔ×÷Óá£
ͼ2.Éöµ¥Î»Ê¾Òâͼ[2]
ƾ֤ϸ°ûÀàÐÍ£¬ÉöÔà¿ÉÒÔ»®·Ö³ö5Àà¹ÌÓÐϸ°û£¬»®·ÖÊÇϵĤϸ°û£¨mesangium£©¡¢ÄÚƤϸ°û£¨endothelium£©¡¢×ãϸ°û£¨podocyte£©¡¢ÉöС¹ÜÉÏƤϸ°ûºÍÉö¼äÖʳÉÏËάϸ°û¡£
ϵĤϸ°û¶ÔÉöСÇòëϸѪ¹Ü¾ßÓÐÖ§³ÖºÍ±£»¤×÷Óã¬ËüÄܵ÷ÀíëϸѪ¹ÜµÄËõ¶ÌºÍÊæÕÅ£¬Í¨¹ýƽºâëϸѪ¹ÜµÄѪÁ÷Á¿£¬¿ØÖÆÂ˹ýĤµÄÂ˹ý¹¦Ð§¡£ÏµÄ¤Ï¸°û»¹¾ßÓÐÍÌʳ¹¦Ð§£¬¿ÉÍÌÊÉһЩ´ó·Ö×ÓÎïÖÊ£¬°üÀ¨²ÐÁôÔÚ»ùµ×ĤÉϵijÁ»ýÎï¡£±ðµÄ£¬ÏµÄ¤Ï¸°û»¹ÄܺÏÉíÉø͸¶àÖÖøºÍÉúÎï»îÐÔÎïÖÊ£¬¼ÓÈë»ùµ×ĤµÄÐÞ¸´¡¢ÃâÒß·´Ó¦¡¢ÉöСÇòÑ×Ö¢·´Ó¦µÈ¶àÖÖÐÄÀíÀú³Ì¡£
ͼ3. ÉöСÇòÇÐÃæÉϲî±ðϸ°ûµÄλÖÃ
ϵĤϸ°ûÊÜËð»áÓ°ÏìÉöСÇòµÄÓÐÓÃÂ˹ýÃæ»ý£¬Ó°ÏìÉöÔàµÄѪҺ¹ýÂ˹¦Ð§£»ÏµÄ¤Ï¸°ûÒì³£ÔöÉúÍùÍùÊÇÉöСÇòÓ²»¯µÄÇ°×ࣻ±ðµÄϵĤϸ°ûÉϱí´ïÓжàÖÖÃâÒßÊÜÌ壬ÆäÒì³£»¹»áµ¼ÖÂÉöÔàÈÝÒ×»¼ÉÏÖÖÖÖѬȾÐÔ¼²²¡¡£
ÄÚƤϸ°û¾ßÓÐά³ÖÉöСÇòëϸѪ¹Ü½á¹¹ÍêÕûµÄÆÁÕϹ¦Ð§£¬ËüÊÇÑ¡ÔñÐÔÂ˹ýÆÁÕϹ¦Ð§µÄµÚÒ»µÀ·ÀµØ£¨70~100nm£©£¬¾ßÓп¹Äý¡¢¿¹ÑªË¨Ðγɺ͵÷ÀíÉöСÇòѪÁ÷¶¯Á¦Ñ§µÄ×÷Ó㬱ðµÄÄÚƤϸ°ûÓëϵĤϸ°ûÒ»Æð¼ÓÈë»ùµ×ĤµÄºÏ³ÉºÍÐÞ¸´¡£ÄÚƤϸ°ûÊÜËðºó£¬Æ俹Äý»îÐÔϽµ£¬µ¼ÖÂÍâÄýѪ΢Ѫ˨µÄÐγɣ»ËüµÄϸ°û±íÐÍÒ²»á±¬·¢¸Ä±ä£¬»áÊÍ·ÅһϵÁе¼ÖÂÉöÔàÏËά»¯µÄϸ°ûÒò×Ó¡£
×ãϸ°ûÊÇÉöСÇòÂ˹ýÆÁÕϵÄÒ»²¿·Ö£¬ÏàÁÚ×ãϸ°ûÍ»ÆðÖ®¼äÐγÉÕ¤À¸×´µÄ½»Ö¯£¬½»Ö¯Ö®¼äµÄåÐÒ£³ÆΪÁѿף¬ÁÑ¿×Ö±¾¶½ÏС£¨40nm£©£¬ÄÜ×è¸ô´ó·Ö×Óͨ¹ý£¬Æðµ½»úеÆÁÕϵÄ×÷Óã»±ðµÄ×ãϸ°û»¹ÄÜÉø͸´ø¸ºµçºÉµÄÍÙÒºËáÌǵ°Ã¸µÈÎïÖÊ£¬Æðµ½µçºÉÆÁÕϵÄ×÷Óá£×ãϸ°ûÊÇÉöÔà×îÈÝÒ×·ºÆ𲡱äµÄϸ°û£¬×ãϸ°ûÊÜËð»áµ¼ÖÂÁѿױÕÈû£¬µçºÉÆÁÕϹ¦Ð§ÕÏ°£¬µ¼ÖÂĤÐÔÉö²¡£»ÑÏÖصĻ¹»á·ºÆð×ãϸ°ûÏËά»¯£¬½ø¶øµ¼ÖÂÉöСÇòÓ²»¯¡£
ͼ4.×ãϸ°ûλÖü°ÐÎ̬[3]
ÉöС¹ÜÉÏƤϸ°ûµÄÖ÷ÒªÐÄÀí¹¦Ð§ÓжÔÔÄò¾ÙÐÐÖØÎüÊÕºÍÏ¡ÊÍ£¬¼á³ÖѪҺµÄµç½âÖÊƽºâºÍËá¼îƽºâµÈ¡£ÉöС¹ÜÉÏƤϸ°ûÊÜËðºó»áµ¼ÖÂÒ¹ÄòÔö¶à£¬µç½âÖÊÔÓÂÒ£¬ËáÖж¾µÈÖ¢×´¡£
¼äÖʳÉÏËάϸ°û¾ßÓÐά³ÖÉöÔàÕý³£½á¹¹µÄ¹¦Ð§£¬Ëü¼ÓÈë×é³ÉÂ˹ýÆÁÕÏ¡¢Í¬Ê±»¹¾ßÓÐÐÞ¸´¹¦Ð§¡£¼äÖʳÉÏËάϸ°ûÊÇ´ÙʹÉöÔ౬·¢ÏËά»¯µÄÒªº¦Ï¸°û£¬²¡ÀíÇéÐÎϼäÖʳÉÏËάϸ°ûµÄÒì³£ÔöÖ³»á±¬·¢´ó×Úϸ°ûÍâ»ùÖÊ£¬½ø¶øµ¼ÖÂÕû¸öÉöÔàµÄÏËά»¯¡£
ÒÑÍù¶ÔÉöϸ°ûµÄ·ÖÀàÖ÷ÒªÊÇƾ֤Æ书Ч¡¢ÆʽâλÖûòÉÙÁ¿±ê¼Ç»ùÒò£¬ÏÖÔÚËæ×ŵ¥Ï¸°û²âÐòÊÖÒյijÉÊìºÍÆÕ±éÓ¦Óã¬ÉöÔ൥ϸ°û²âÐòµÄÎÄÕÂÔ½À´Ô½¶à£¬ÅжϳöµÄϸ°ûÀàÐÍÒ²Ô½À´Ô½¶à¡£ÏÖÔÚ·¢Ã÷³ýÁË5Àà¹ÌÓÐϸ°ûÍ⣬ÉöÔàÖÐÉÐÓмä³äÖÊϸ°û¡¢µ¥ºËϸ°û¡¢·Ê´óϸ°ûµÈ¶àÖÖ²î±ðϸ°û¡£
ͼ5.ÉöÔàϸ°û·ÖÐÍ[4]
ÄÏÄ£ÉúÎïÔÚСÊóÃÚÄòϵͳ£¨°üÀ¨ÉöÔࣩÌض¨Ï¸°ûÀàȺmarker»ùÒòÖÐÇÃÈëCreÖØ×éøԪ¼þ»ò±¨¸æ»ùÒò£¬Ñо¿Õß¿ÉÒÔ¶ÔÿÀàϸ°û¾ÙÐбê¼Ç£¬»¹¿ÉÒÔÔÚÌض¨Ï¸°ûȺÀï¾ÙÐлùÒò¼°Ï¸°û¹¦Ð§µÄÑо¿¡£Ïêϸģ×ÓÐÅÏ¢¼ûÏÂ±í£º
¹ØÓÚÉöÔ༲²¡£¬ÎÒÃÇÍùÍùÓÐ2¸öÊìϤÉϵÄÎóÇø¡£µÚÒ»£¬ËäÈ»±£½¡Æ·³§¼ÒÆÌÌì¸ÇµØµÄÐû´«ÉöºÃÐÔ¹¦Ð§ºÃ£¬µ«ÏÖʵÉÏÁ½Õß²¢ÎÞ¹ØÁª£»µÚ¶þ£¬ÉöÔ༲²¡µÄ·¢²¡ÂÊ×ÅʵºÜ¸ß£¬È«Çòƽ¾ùÿʮСÎÒ˽¼ÒÖоÍÓÐÒ»¸öÂýÐÔÉö²¡»¼Õߣ¬½öÎÒ¹ú¾ÍÓÐ1ÒÚ¶àÈË¡£Éö²¡ÒѳÉΪ¼ÌÐÄÄÔѪ¹Ü¼²²¡¡¢Ö×Áö¡¢ÌÇÄò²¡Ö®ºó£¬ÈËÀàÉúÃü¿µ½¡ÃæÁÙµÄÖ÷ÒªÍþв֮һ¡£ÏÂÃæС±àΪ¸÷ÈËÏÈÈݼ¸ÖÖ³£¼ûµÄÉöÔ༲²¡ºÍÏìÓ¦µÄÑо¿Ä£×Ó¡£
ÃâÒßÇòÂÑ°×A£¨IgA£©Éö²¡ÊÇÌìϹæÄ£ÄÚ×î³£¼ûµÄÔ·¢ÐÔÉöСÇò¼²²¡£¬Ò²ÊÇÎÒ¹ú×î³£¼ûµÄÉöСÇò¼²²¡£¬Õ¼Ô·¢ÐÔÉöСÇòÉöÑ×µÄ30%-40%¡£IgAÉö²¡¿ÉÌåÏÖΪÖÖÖÖÁÙ´²×ÛºÏÕ÷£¬°üÀ¨ÎÞÖ¢×´ÐÔѪÄò»òÂÑ°×Äò¡¢ÂýÐÔÉöСÇòÉöÑס¢¼±½øÐÔÉöÑ×»òÉö²¡×ÛºÏÕ÷¡£IgAÉö²¡µÄ²¡Àí»úÖÆ»¹Î´ÍêÈ«Ã÷È·£¬ÏÖÔÚ±»ÆÕ±é½ÓÊܵÄÀíÂÛÒÔΪ£¬IgAÉö²¡ÊǶàÖÖ»úÖÆÅäºÏµ¼Öµģ¬¶ø·Ç¼òµ¥»úÖÆ£¬±»³ÆΪ¡°¶àÖع¥»÷¼Ù˵¡±£¬´Ë¼Ù˵ÓÐ4¸ö»·½Ú£º¢ÙÒì³£ÌÇ»ù»¯IgA1£¬½ø¶øÌìÉúGd-IgA1£»¢Ú±»Ñ»·ÏµÍ³Öп¹¾ÛÌǵÄ×ÔÉí¿¹Ìåʶ±ð£»¢Ûµ¼ÖÂÉöÑ×µÄÃâÒ߸´ºÏÎï³Á»ýÔÚϵĤÇø£»¢Ü¼¤»îϵĤϸ°û¡£
ͼ6.ÉöСÇòÉöÑ×±¬·¢Ê¾Òâͼ[5]
×î½üµÄÑо¿Åú×¢£¬Õ³Ä¤ºÍ²¹ÌåÃâÒßϵͳÔÚIgAÉö²¡ÖÐҲʩչÖ÷Òª×÷Óá£ÀýÈ磬ѪÄòµÄ·ºÆðºÍճĤÃâÒßÏà¹Ø£¬¶øÑ»·ÃâÒ߸´ºÏÎïÖг£³£¿ÉÒÔ·¢Ã÷²¹Ì壬ÀýÈçC3²¹ÌåºÍ²¹ÌåÒò×ÓH¡£
ÔÚÈËÀàÖУ¬IgAµÄÖ÷ÒªÊÜÌåΪCD89£¬¶øСÊó²»±í´ïCD89£¬Òò´ËΪÁ˹¹½¨ÀàÈ˱íÐ͵ÄIgAÉö²¡Ä£×Ó£¬ÉÏÊÀ¼Í¾ÅÊ®ÄêÔÂÄ©£¬Launay¿ª·¢ÁËÓÉCD11bÆô¶¯×Ó¿ØÖƵġ¢±í´ïÈËCD89µÄת»ùÒòСÊó[9]¡£¸ÃСÊóÔÚµ¥ºËϸ°û/¾ÞÊÉϸ°ûÉϱí´ïÈ˵ÄCD89£¬ÔÚÉú³¤ÍíÆÚ£¬·ºÆðIgAµÄÉöСÇòÄÚ³Á»ý¡¢ÏµÄ¤À©Õź;ÞÊÉϸ°û½þÈó¡£
Êܵ½¸ÃÑо¿Æôʾ£¬ÄÏÄ£ÉúÎï¹¹½¨ÁËItgam-IRES-hCD89СÊóÄ£×Ó£¬¿ÉÀû±ãÈ«Çò¿Æѧ¼Ò¾ÙÐÐIgAÉö²¡Ñо¿¼°ÐÂÒ©Ñз¢¡£
Éö°©£¬ÓÖ³ÆÉöϸ°û°©£¨RCC£©£¬ÊÇÃÚÄòϵͳ×î³£¼ûµÄÖ×ÁöÖ®Ò»£¬ÔÚÎÒ¹úÉö°©·¢²¡Âʽö´ÎÓÚ°òë×°©£¬Î»¾ÓÃÚÄòϵͳÖ×ÁöµÚ2λ¡£Éö°©ÓжàÖÖ²î±ðµÄÀàÐÍ£¬ÈçÉö͸Ã÷ϸ°û°©¡¢ÈéÍ·×´Éöϸ°û°©¡¢ÉöÏÓɫϸ°û°©¡¢¶à·¿ÄÒÐÔÉöϸ°û°©µÈ£¬ÆäÖÐÉö͸Ã÷ϸ°û°©×î³£¼û£¬Ô¼Õ¼ËùÓÐÉö°©µÄ90%¡£Éö°©¿É·ÖΪËÄÆÚ£¬·¢Ã÷µÄÔ½ÔçÔ¤ºóÔ½ºÃ£¬IÆÚ¡¢IIÆÚÉö°©µÄ5ÄêÉúÑÄÂÊ»®·Ö¿É´ï95%ºÍ88%£¬¶øIVÆÚÉö°©µÄ5ÄêÉúÑÄÂʽöÓÐ20%¡£
ͼ7.ÉöÖ×Áö¾ÞϸÓëÉúÑÄÂÊ[6]
Éö°©µÄ·¢²¡Óë¶à¸ö»ùÒòÇ×½üÏà¹Ø£¬È磺
- VHL»ùÒò£ºÆäÍ»±ä²»µ«Óë¼Ò×åÐÔµÄ͸Ã÷Éöϸ°û°©£¨CCRCC£©Óйأ¬²¢ÇÒ70%ÒÔÉϵÄÉ¢·¢ÐÔCCRCCÒ²´øÓÐVHLÍ»±ä£¬ÊÇÏÖÔÚÉö°©ÖÐÍ»±äÂÊ×î¸ßµÄÉöÖ×ÁöÒÖÖÆ»ùÒò¡£
- PBRM1»ùÒò£ºÖ÷ÒªÓëCCRCCÓйأ¬ÔÚCCRCCÖеÄÍ»±äÂÊ´ï40%£¬½ö´ÎÓÚVHL»ùÒò¡£
- FLCN»ùÒò£º¸Ã»ùÒòÍ»±ä¿ÉÒýÆðBirt Hogg Dube×ÛºÏÕ÷£¬¸Ã²¡»¼ÕßÈ«Éí¶à´¦»á·ºÆðÏËάëÄÒÁö£¬Ô¼ÓÐ34%µÄBHD²¡ÈË»áÉú³¤³ÉÉö°©¡£
³ýÉÏÊöÖ÷Ҫͻ±ä»ùÒòÍ⣬ÉÐÓÐFH¡¢TSC1/TSC2¡¢MET¡¢SETD2¡¢BAP1¡¢JARID1c/KDM5C¡¢UTX/KDM6A¡¢NF2¡¢MLL2¡¢CUL7ºÍBRTCµÈ»ùÒòÓëÉö°©·¢²¡±£´æÒ»¶¨µÄ¹ØÁª¡£
ZacharyʹÓÃNF2-floxСÊóÓëVillin-Cre½»Å䣬»ñµÃÁË¿ÉÒÔ×Ô¾õÉö°©µÄСÊóÄ£×Ó[10]£¬ÆäÔÚ 15 ÈÕÁäʱ¾Í¿ÉÒÔÊӲ쵽ÉöС¹ÜÉÏƤµÄËðÉË£¬µ½ 3 ¸öÔ´óʱ£¬»á·ºÆðÉöС¹Ü¹ÜÄÚÁö±ä£¬µ½ 6 ¸öÔÂʱ£¬Ö×ÁöµÄ¾ÞϸºÍÊýÄ¿ÔöÌí£¬¿ÉÒÔ´©Í¸Ð¡¹Ü»ùµ×Ĥ£¬Ï£ÍûΪ½þÈóÐÔ°©¡£
Êܵ½¸ÃÑо¿Æôʾ£¬ÄÏÄ£ÉúÎï¹¹½¨ÁËNF2-floxСÊó£¬Àû±ãÈ«Çò¿Æѧ¼Ò¾ÙÐÐ×Ô¾õÉö°©Ä£×Ó¹¹½¨£¬³ý´ËÖ®Í⣬»¹¹¹½¨ÁËÉö°©±¬·¢Ïà¹Ø»ùÒòVHL¡¢PBRM1µÄÇóýºÍÌõ¼þÐÔÇóýСÊóÄ£×Ó£¬Àû±ãÉö°©±¬·¢ÆøÀíÑо¿¡£ÏêϸµÄÄ£×ÓÐÅÏ¢¼ûÎÄÄ©±í¸ñ±í¸ñ¡£
ÄÒÐÔÉö²¡ÊÇÖ¸ÔÚÉöÔà·ºÆ𵥸ö»ò¶à¸öÄÚº¬ÒºÌåµÄÁ¼ÐÔÄÒÖ×ÐÔÉöÔ༲²¡£¬ÒÔ´¿´âÐÔÉöÄÒÖ××î³£¼û£¬Æä´ÎΪ¶àÄÒÉö¡£ÉöÔ೬Éù¼ì²éÒѳÉΪ»ù´¡µÄÌå¼ìÏîÄ¿£¬¶øÔ½À´Ô½¶àµÄÈËÒ²±»³¬Éù±¨¸æµ¥ÉϵÄ×óÉöÄÒÖ×»òÓÒÉöÄÒÖס¢ÉõÖÁË«ÉöÄÒÖ×ÕâÑùµÄ±¨¸æËùÀ§ÈÅ¡£ÏÖʵÉÏ£¬´¿´âÐÔÉöÄÒÖ×ÊdzÉÄêÈËÉöÔà×î³£¼ûµÄÒ»ÖֽṹÒì³££¬Õ¼ËùÓÐÄÒÖ×ÐÔÉöÔ༲²¡µÄ70%×óÓÒ£¬·¢²¡ÂÊËæÄêËêÔöÌí¶øÔö¶à¡£ÈôÊÇûÓÐÖ¢×´£¬¶ÔÉöÔ๦ЧºÍÖÜΧ×éÖ¯Ó°Ïì²»´ó£¬´¿´âÐÔÉöÄÒÖ×Ò»Ñùƽ³£ÊDz»ÐèÒªÖÎÁƵģ¬Ö»ÒªÃ¿°ëÄêµ½Ò»ÄêËæÕï¾Í¿ÉÒÔ¡£
ͼ8.PKD1Í»±äÓë¶àÄÒÉöµÄÏà¹ØÐÔ[7]
¶àÄÒÉö²¡£¨PKD£©µÄΣº¦Ôò´óµÃ¶à£¬PKDÊÇ×î³£¼ûµÄÒÅ´«ÐÔÉöÔ༲²¡£¬°üÀ¨³£È¾É«ÌåÏÔÐÔÒÅ´«ÐÔÉö²¡£¨ADPKD£©ºÍ³£È¾É«ÌåÒþÐÔÒÅ´«ÐÔÉö²¡£¨ARPKD£©¡£ADPKD¾ßÓÐÒÅ´«ÒìÖÊÐÔ£¬Î»ÓÚ16ºÅȾɫÌåÉϵÄPKD1»ùÒò£¨¼ûÓÚ85%µÄ²¡Àý£©»òλÓÚ4ºÅȾɫÌåÉϵÄPKD2»ùÒò£¨¼ûÓÚ15%µÄ²¡Àý£©Í»±äÓë·¢²¡Ç×½üÏà¹Ø¡£PKD1ºÍPKD2»ùÒò»®·Ö±àÂëÍêÕûµÄĤÂѰ׶àÄÒÂÑ°×-1ºÍ¶àÄÒÂÑ°×-2£¬Á½Õ߽ṹÏàËÆ£¬¿É±¬·¢Ï໥×÷Óá£PKD1»òPKD2µÄÍ»±ä¿Éµ¼ÖÂÐźÅʧµ÷£¬»·Á×ËáÏÙÜÕˮƽÉý¸ß£¬×îÖÕµ¼ÖÂÄÒÖ×ÌìÉú¡£
ÉÏÊÀ¼Í90ÄêÔÂÄ©£¬Zhou JµÈͨ¹ýͬԴÖØ×齫 Pkd1 ½Ø¶ÏÍ»±äÒýÈëСÊó£¬Ä£Äâ ADPKD Öз¢Ã÷µÄÍ»±ä¡£Pkd1ÇóýÔÓºÏ×ÓСÊóûÓÐÏÔ×ŵıíÐÍ£¬¶ø´¿ºÏ×ÓÔÚΧ²úÆÚéæÃü£¬°éÓдó×ÚÔö´óµÄÉöÄÒÖס¢ÒȹÜÄÒÖ׺ͷη¢Óý²»Á¼¡£ÉöÄÒÖ×µÄÐγÉʼÓÚÅßÌ¥µÚ 15.5 Ìì (E15.5) ÔÚ½ü¶ËС¹ÜÖУ¬²¢Ñ¸ËÙÏ£ÍûÒÔÈ¡´úÕû¸öÉöʵÖÊ¡£µ½³öÉúºóµÚ8Ì죬´æ»îµÄ´¿ºÏ×ÓСÊóÉöʵÖÊÏÕЩÍêÈ«±»ÄÒÖ×È¡´ú[11]¡£ÊܸÃÑо¿Æôʾ£¬ÄÏÄ£ÉúÎï×ÔÖ÷¹¹½¨ÁËPKD1ÇóýºÍÌõ¼þÐÔÇóýµÄСÊ󣬿ÉÓÃÓÚ¶àÄÒÉö²¡µÄÑо¿£¬Ïêϸģ×ÓÐÅÏ¢¼ûÎÄÄ©±í¸ñ¡£
¾ÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯£¨FSGS£©²¢²»ÊÇÌض¨µÄ¼²²¡£¬¶øÊÇÒ»ÖÖ²¡Àí¸Ä±ä¡£Ëü¼È¿ÉÒÔÐÎòÒÔÔ·¢ÐÔ×ãϸ°ûËðÉËΪÌØÕ÷µÄ¼²²¡£¬Ò²¿ÉÒÔÐÎòÆäËüÀàÐÍÂýÐÔÉöÔ༲²¡£¨CKD£©Öеļ̷¢²¡±ä¡£FSGS Ö÷Òª·ÖΪԷ¢ÐÔ¡¢¼Ì·¢ÐÔºÍÒÅ´«ÐÔÈýÀà¡£ÆäÖÐÔ·¢ÐÔÊÇÓÉÉöÔà×Ô¼ºµÄ²¡±äµ¼Ö£»¼Ì·¢ÐÔÔòÊÇÖ¸ÓÐÃ÷È·µÄ²¡Òò£¬°üÀ¨²¡¶¾£¨HIV£©¡¢Ò©ÎïºÍ¶¾ËØ£¨ï®Öж¾£©¡¢Éö×éÖ¯ïÔÌ£¨ÁæØêÉö£©¡¢ÉöȱѪȱÑõ£¨¸ßѪѹÉöË𺦡¢Éö¶¯ÂöÏÁÕ£©¡¢ÖضȷÊÅֵȡ£
ͼ9.FSGSµÄ³£¼ûÓÕÒò[8]
ÒýÆðFSGSµÄÖ²¡»ùÒò°üÀ¨ NPHS1/2¡¢CD2AP¡¢MYO1E¡¢MYO9AµÈ£¬ÕâЩ»ùÒòÍ»±äÒýÆðµÄ FSGS ¾ßÓг£È¾É«ÌåÒþÐÔÒÅ´«µÄÌص㣬»¼Õß³£ÓÚ¶ùͯʱÆÚ·¢²¡¡£a-actinin-4¡¢TRPC6 ºÍ INF2 µÄÍ»±äÔòÌåÏÖΪ³£È¾É«ÌåÏÔÐÔÒÅ´«£¬»¼Õ߶àÓÚ³ÉÈËÆÚ·¢²¡£¬Ò»Ñùƽ³£ÎÞÏÔ×ŵÄÉö²¡×ÛºÏÕ÷ÌåÏÖ¡£
Indra R Gupta ºÍAlda Tufro»®·Ö¹¹½¨ÁËCd2apºÍMyo9aÇóýµÄСÊ󣬷¢Ã÷ÕâЩСÊó»á·ºÆðÉöÔà·¢ÓýÒì³£¡¢ÂÑ°×Äò¡¢ÉöС¹ÜήËõµÈFSGS¼²²¡µÄÖ¢×´[12,13]¡£ÊÜ´ËÆô·¢£¬ÄÏÄ£ÉúÎï×ÔÖ÷¹¹½¨ÁËCd2apºÍMyo9aµÄÇóýСÊóÄ£×Ó£¬¿ÉÓÃÓÚFSGSµÄÑо¿£¬Ïêϸģ×ÓÐÅÏ¢¼ûÎÄÄ©±í¸ñ¡£
ÄÏÄ£ÉúÎï×ÔÖ÷¹¹½¨Á˶àÖÖ»ùÒòÐÞÊÎСÊ󣬿ÉÓÃÓÚIgAÉöСÇòÉöÑס¢Éö°©¡¢ÄÒÐÔÉöµÈ¶àÖÖÉöÔ༲²¡µÄÑо¿ºÍÒ©Îïɸѡ¡£Ïêϸģ×ÓÐÅÏ¢¼ûÏÂ±í£º
ÄÏÄ£ÉúÎïÉî¸û»ùÒò±à¼ÁìÓò£¬Ìṩȫ·½Î»Ä£Ê½ÉúÎïЧÀÍ£¬°üÀ¨»ùÒòÐÞÊÎÖÆÆ·Ä£×Ó¹©Ó¦¡¢¸öÐÔ»¯Ä£×Ó¶¨ÖÆ¡¢ËÇÑø·±Óý¡¢±íÐÍÆÊÎö¡¢Ò©Ð§ÆÀ¼ÛµÈ£¬Öª×ã²î±ðʵÑéÊÒÐèÇó¡£
[1]ϵͳÆʽâѧµÚ°Ë°æ. °ØÊ÷Áî Ó¦´ó¾ý
[2]Science. 2018 August 10; 361(6402): 594¨C599.
[3]Nat Rev Dis Primers. ; 6(1): 68. doi:10.1038/s41572-020-0196-7.
[4]http://humphreyslab.com/SingleCell/
[5]Stahl, Rolf; Hoxha, Elion (2016). Glomerulonephritis. DMW - Deutsche Medizinische Wochenschrift, 141(13), 960¨C968. doi:10.1055/s-0042-107410
[6]Cohen, Herbert T.; McGovern, Francis J. (2005). Renal-Cell Carcinoma. New England Journal of Medicine, 353(23), 2477¨C2490. doi:10.1056/NEJMra043172
[7]Nat Rev Dis Primers . 2018 Dec 6;4(1):50. doi: 10.1038/s41572-018-0047-y. Polycystic kidney disease
[8]Bose, B.; Cattran, D. (2014). Glomerular Diseases: FSGS. Clinical Journal of the American Society of Nephrology, 9(3), 626¨C632. doi:10.2215/CJN.05810513
[9]Launay P , Grossetete B , Arcos-Fajardo M , et al. Fc¦Á Receptor (Cd89) Mediates the Development of Immunoglobulin a (Iga) Nephropathy (Berger's Disease)[J]. Journal of Experimental Medicine, 2000, 191(11):1999-2010.
[10]Morris Z S , Mcclatchey A I . Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma[J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(24):9767-9772.
[11]Nat Genet. 1997 Oct;17(2):179-81.doi: 10.1038/ng1097-179.Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation
[12] Case Reports Kidney Int . 2019 Jan;95(1):57-61. doi: 10.1016/j.kint.2018.08.014. Epub 2018 Oct 26. Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice
[13] Kidney Int . 2021 May;99(5):1102-1117. doi: 10.1016/j.kint.2020.12.022. Epub 2021 Jan 4. Rho-GTPase Activating Protein myosin MYO9A identified as a novel candidate gene for monogenic focal segmental glomerulosclerosis